Last reviewed · How we verify
Prolopa®
At a glance
| Generic name | Prolopa® |
|---|---|
| Also known as | Prolopa® 100-25 |
| Sponsor | Bial - Portela C S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Relative Bioavailability Study of HRG2010 in Healthy Subjects (PHASE1)
- Dopamine, Reward Learning and Sex Hormones (NA)
- Levodopa Benserazide Generic Formulation Versus the Originator (PHASE4)
- Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With "Wearingoff" Phenomenon (PHASE2)
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg (PHASE1)
- Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics (PHASE1)
- Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics (PHASE1)
- Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prolopa® CI brief — competitive landscape report
- Prolopa® updates RSS · CI watch RSS
- Bial - Portela C S.A. portfolio CI